Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression

Oncogenic KIT or PDGFRA receptor tyrosine kinase (TK) mutations are compelling therapeutic targets in gastrointestinal stromal tumors (GISTs), and the KIT/PDGFRA kinase inhibitor, imatinib, is the standard of care for patients with metastatic GIST. However, approximately 10% of KIT-positive GIST met...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Tu, Yuqing, Zuo, Rui, Ni, Nan, Eilers, Grant, Wu, Duolin, Pei, Yuting, Nie, Zuoming, Wu, Yeqing, Wu, Yuehong, Ou, Wen-Bin
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300111/
https://ncbi.nlm.nih.gov/pubmed/30488756
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2018.1553335
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados